TABLE 3.

Association of HDL-C alterations with changes in ADN or its fractions

Change in HDL-C
Modela	B	SE	P	R
Part I. Basic Models
Model A				0.086
ILI v. DSE	2.331	0.356	<0.0001
Model B				0.129
ILI v. DSE	1.896	0.351	<0.0001
Δ ADN	0.518	0.063	<0.0001
Model C				0.122
ILI v. DSE	1.895	0.354	<0.0001
Δ HMW-ADN	0.759	0.102	<0.0001
Model D				0.116
ILI v. DSE	2.105	0.351	<0.0001
Δ Non-HMW-ADN	0.848	0.124	<0.0001
Part II. Full Models
Model E				0.176
ILI v. DSE	1.011	0.403	0.012
Δ ADN	0.442	0.063	<0.0001
Δ Weight	−0.056	0.029	0.053
Δ Fitness	0.195	0.150	0.19
Δ HbA1c	−0.158	0.189	0.40
Δ Triglycerides	−0.012	0.002	<0.0001
Model F				0.170
ILI v. DSE	1.028	0.405	0.011
Δ HMW-ADN	0.63	0.102	<0.0001
Δ Weight	−0.053	0.029	0.068
Δ Fitness	0.219	0.151	0.15
Δ HbA1c	−0.146	0.190	0.44
Δ Triglycerides	−0.012	0.002	<0.0001
Model G				0.169
ILI v. DSE	1.047	0.405	0.0098
Δ Non-HMW-ADN	0.740	0.121	<0.0001
Δ Weight	−0.067	0.029	0.0214
Δ Fitness	0.210	0.151	0.1635
Δ HbA1c	−0.237	0.189	0.2092
Δ Triglycerides	−0.012	0.002	<0.0001
Model H				0.176
ILI v. DSE	1.011	0.403	0.0123
Δ HMW-ADN	0.418	0.120	0.0005
Δ Non-HMW-ADN	0.472	0.143	0.0010
Δ Weight	−0.057	0.029	0.0516
Δ Fitness	0.194	0.150	0.1957
Δ HbA1c	−0.162	0.189	0.3942
Δ Triglycerides	−0.012	0.002	<0.0001

^aEach was analyzed independently and adjusted for baseline HDL-C, age, gender, race/ethnicity, clinic site, history of CVD (defined in Table 1), diabetes duration, current smoking, and use of insulin, thiazolidinediones, statins, and hormone replacement in women.

“ILI vs DSE” is an indicator for treatment group. An interaction term ILI* gender was evaluated in the full models (E–G) and was nonsignificant (P = 0.675 for total ADN, P = 0.746 for HMW-ADN, and P = 0.5983 for non-HMW-ADN). Sums of squares for Δ HMW-ADN and Δ non-HMW-ADN were 476.9 and 427.6 in Model H.